1. Introduction {#j_med-2018-0020_s_001}
===============

Arginine vasopressin (AVP) is a nine-amino-acid peptide hormone synthesized in the hypothalamus and stored in vesicles at the posterior pituitary \[[@j_med-2018-0020_ref_001]\]. Its main physiologic functions are re-absorption of water in the renal collecting ducts, and vasoconstriction \[[@j_med-2018-0020_ref_002]\]. In the anterior pituitary, AVP acts *via* V1b receptors \[[@j_med-2018-0020_ref_003]\]. *Via* the hypothalamus-pituitary-adrenal axis, it influences the regulation of adrenocorticotropic hormone (ACTH) secretion by the pituitary gland and as a consequence, release of corticosteroid by the adrenal glands \[[@j_med-2018-0020_ref_004]\]. AVP acts as a chemoattractant for small cell lung carcinoma cells and possibly for monocytes similar to bombesin \[[@j_med-2018-0020_ref_005]\]. Interestingly, in circulating blood cells, AVP almost exclusively binds to mononuclear phagocytes and much less to lymphocytes and polymorphonuclear leukocytes \[[@j_med-2018-0020_ref_006]\].

AVP has direct, high-affinity vasopressin V1a receptor-mediated pro- and anti-inflammatory effects on human leukocytes \[[@j_med-2018-0020_ref_004], [@j_med-2018-0020_ref_007]\]. *In vitro*, AVP induces production of interferon-gamma (IFN-γ) \[[@j_med-2018-0020_ref_008]\] and enhances lymphocyte response. Furthermore, AVP has immunomodulatory properties jointly with other vasoactive catecholamines \[[@j_med-2018-0020_ref_009], [@j_med-2018-0020_ref_010]\] and enhances macrophage phagocytosis. AVP-induced rapid release of oxygen radical and hydrogen peroxide (respiratory burst) degrades internalized particles, and in combination with hypochlorite, it directly destroys bacteria. Phagocytosis and subsequent respiratory burst are integral components of the immune response. In immune-deprived intensive care patients with systemic inflammation and septic shock, administration of AVP is frequently the mainstay of treatment.

We investigated the effects of AVP on migration and chemotaxis of and oxygen free radical release by human leukocytes *in vitro*. Results of our study may provide new insights into endogenous inhibition of inflammation and elucidate the potential benefits of AVP administration in patients with septic shock.

2. Methods {#j_med-2018-0020_s_002}
==========

2.1. Study design {#j_med-2018-0020_s_002_s_001}
-----------------

An experimental study was performed in the medical laboratories of the university hospital of Innsbruck. This study was approved by the Ethics Committee of the Medical University Innsbruck. Written informed consent was obtained from all participants prior to inclusion in the study. Participation in the study was voluntary and based on the understanding that results will be published in scientific journals.

Neutrophils and monocytes were obtained from peripheral blood samples of ten healthy volunteers (10 mL samples, each anti-coagulated with 1.6 mg EDTA/ mL blood). Neutrophils were prepared after lymphoprep density gradient centrifugation by dextran sedimentation followed by hypotonic lysis of contaminating erythrocytes with potassium chloride solutions as previously described \[[@j_med-2018-0020_ref_011]\]. After lymphoprep density gradient centrifugation, cells were collected and washed three times with normal saline. Biocoll (15 mL) separating solution was carefully covered with the blood and centrifuged at 300xg for 20 min. The peripheral blood mononuclear cell (PBMC) layer was carefully obtained and again centrifuged for 10 min at 300xg. The resulting cell pellet was resuspended in a standard solution consisting of RPMI1640 enriched with 0.5 % BSA. After determining of the amount of PBMCs, CD14+ monocytes were isolated from PBMCs with magnetic cell sorting according to the manufacturer's protocol (Miltenyi Biotec).

2.2. Chemical substances {#j_med-2018-0020_s_002_s_002}
------------------------

Bovine albumin serum (BSA) was from Sigma Chemical Corp (St. Louis, MO). For density centrifugation, Biocoll from Biochrome AG (Berlin, Germany) was used. The MACS Monocyte isolation kit II was from Miltenyi Biotec® (Bergisch Gladbach, Germany). RPMI 1640 with phenol red was from Biological industries (Kibbutz Beit Haemek, Israel). The nitrocellulose filter (5 μm pore size) was from Sartorius AG (Goettingen, Germany). Hank's balanced salt solution without calcium and magnesium was purchased from GIBCO BRL, Life Technologies (Vienna, Austria) and phosphate buffered saline (PBS) was from PAA (Linz, Austria). All other reagents not further specified were obtained from Sigma Chemical Corp (St. Louis, MO). All stock solutions were stored at -20°C. Vasopressin (BCN Peptides; Barcelona, Spain) was stored in PBS at a concentration of 10^--3^ M at -20°C and diluted in assay medium for the experiments.

2.3. Chemotaxis experiments {#j_med-2018-0020_s_002_s_003}
---------------------------

Migration of leukocytes was measured using a modified 48-blind well microchemotaxis chamber (Neuro Probe, Cabin John, MD) equipped with 5-μm pore sized nitrocellulose filters for neutrophil or monocyte chemotaxis \[[@j_med-2018-0020_ref_017]\]. After washing, 50 μL of cell suspension (1 × 10^6^ cells/mL) were put into the upper compartment of the chemotaxis chamber, and cells were allowed to migrate for 25 min (neutrophils) and 45 min (monocytes) toward different concentration gradients of the soluble chemoattractants N-formyl-Met-Leu-Phe (fMLP) or interleukin 8 and vasopressin in the lower wells. Fresh culture medium served as control substance. Chemotactic responses were tested in the range 10^--5^ to 10^--15^ M. After these migration periods, the filters were dehydrated, fixed, and stained with hematoxylin and eosin. Migration depth was quantified by microscopy, measuring the distance (μm) from the surface of the filter to the front line of the leading three cells. To investigate deactivation of migration by pre-treatment, cells were incubated for 30 min with different concentrations of vasopressin and chemoattractants and washed twice before testing for chemotaxis.

2.4. Respiratory burst activity of neutrophils {#j_med-2018-0020_s_002_s_004}
----------------------------------------------

PMN were placed in a humidified incubator (37°C, 5% CO2) for various time periods with medium (basal activity) or triggering agents (stimulated activity): 1 μM N-formyl-Met-Leu-Phe (fMLP; Sigma Aldrich, Munich, Germany) or 324 nM phorbol 12-myristate 13-acetate (PMA; Sigma Aldrich, Munich, Germany). Respiratory burst activity was measured using H2DCFDA as a fluorochrome. The assay is based on the oxidation of non-fluorescent H2DCFDA to highly fluorescent 2'-7' dichlorofluorescein (DCF), both intracellularly and extracellularly \[[@j_med-2018-0020_ref_013]\]. Fluorescent activity was determined at 485 ± 20 nm excitation and 530 ± 25 nm emission wavelengths using a multiwell plate reader (Tecan Infinite M200)). Neutrophil respiratory burst activity was detected by an assay using 2',7'dichlorofluorescin diacetate (DCFH-DA), as described previously \[[@j_med-2018-0020_ref_012]\]. This assay is based on the oxidation of nonfluorescent DCFH-DA to the highly fluorescent 2',7'-dichlorofluorescein (DCF) both intracellularly and extracellularly \[[@j_med-2018-0020_ref_014]\]. Neutrophils were primed for 30 min at 37°C (5% CO~2~ atmosphere) with various concentrations of vasopressin, washed twice, and resuspended in Hanks' balanced salt solution (HBSS). Thereafter, 100 μL/well (96-well plate) of 2 x 10^5^ neutrophils were immersed at 37°C in a 10-μml/L solution of DCFH-DA in phenol red-free HBSS containing 1 μmol/L N-formyl-Met-Leu-Phe (fMLP, as a triggering agent) or medium. The plates were covered with lids and placed in a humidified incubator for various time periods. Fluorescence activity was determined at 485 ± 25 nm excitation and 530 ± 25 nm emission wavelengths using a multi-plate reader (Tecan Infinite M200). Readings were taken every 10 min for 1 h. Oxygen free radical release was expressed as fluorescence arbitrary unit.

2.5. Definitions {#j_med-2018-0020_s_002_s_005}
----------------

"Chemotaxis index" defines the ratio between the distance of directed and undirected migration. Leukocyte chemotaxis describes the movement of leukocytes toward sites of inflammation directed by extracellular gradients of diffusible chemicals \[[@j_med-2018-0020_ref_014]\]. In contrast, chemokinesis describes the non-vectorial movement of cells prompted by chemicals \[[@j_med-2018-0020_ref_015]\]. Checkerboard analysis can display alterations of speed, frequency and direction of migration. In this study, we used checkerboard dilution assay as a type of Boyden chamber assay for leukocyte chemokinesis and chemotaxis \[[@j_med-2018-0020_ref_016]\].

2.6. Statistical analysis {#j_med-2018-0020_s_002_s_006}
-------------------------

Non-parametric test was used for calculations of related samples. Data were expressed as mean and SEM. Means were compared by Mann-Whitney U test or paired Student's *t*-test after Kruskal-Wallis analysis of variance. Analyses were performed using GraphPad Prism 7 (La Jolla, CA) or SPSS 16.0 software (SPSS Inc., Chicago, IL).

3. Results {#j_med-2018-0020_s_003}
==========

A total of ten blood samples were investigated in 5 examinations.

3.1. Chemotactic index {#j_med-2018-0020_s_003_s_001}
----------------------

Following 25 min incubation of neutrophils against fMLP and different concentrations of AVP, the mean migration depth was 86.08±14.56 μm. The chemotactic index for neutrophils ranged from 110.2 to 123.3% ([Fig.1A](#j_med-2018-0020_fig_001){ref-type="fig"}). After 45 min incubation of monocytes, the mean migration depth was 116.0 + 14.1 pm. Data expressed as chemotactic index ranged from 110.8% to 116.8% ([Fig.1B](#j_med-2018-0020_fig_001){ref-type="fig"}). Following 30 min pre-incubation with, various concentrations of AVP and migration against fMLP at 37°C the mean migration depth for neutrophils was 69.4 + 9.4 μm. The chemotactic index for neutrophils ranged from 101.6% to 127.9 % ([Fig.2A](#j_med-2018-0020_fig_002){ref-type="fig"}). The mean migration depth for monocytes was 70.8 + 11.6 μm; the chemotactic index ranged between 99.86% and 127.77% ([Fig.2B](#j_med-2018-0020_fig_002){ref-type="fig"}). Priming of the leukocytes with different concentrations of AVP and migration against AVP 10-9 M resulted in deactivation of the migratory response ([Fig. 3A](#j_med-2018-0020_fig_003){ref-type="fig"} and [3B](#j_med-2018-0020_fig_003){ref-type="fig"}).

![Direct chemotaxis against different concentrations of AVP\
PMNs (A) and monocytes (B) remained untreated and were allowed to migrate towards medium (control), fMLP \[10^--8^ M\] and different concentrations of AVP. After fixing and staining the filters, migration depth was evaluated microscopically. Data are expressed as mean ± SD of the Chemotactic Index, which is the ratio between the distance that cells migrated towards the tested substances and that toward the control medium. Statistical analyses: Mann-Whitney U test \[^∗∗^, p\<0.01, ^∗∗∗^, p\<0.0001\]](med-13-122-g001){#j_med-2018-0020_fig_001}

![Priming cells with different concentrations of AVP\
PMNs (A) and monocytes (B) were pre-incubated with different concentrations of AVP for 30 min and migrated against fMLP \[10-8 M\]. Migration towards medium served as the negative control, as positive control, migration against fMLP \[10-8 M\]. Statistical analyses: Mann-Whitney U test \[n.s., not significant, ^∗^, p\<0.05, ^∗∗^, p\<0.01, ^∗∗∗^, p\<0.0001\]](med-13-122-g002){#j_med-2018-0020_fig_002}

![Priming cells with different concentrations of AVP\
PMNs (A) and monocytes (B) were pre-incubated with different concentrations of AVP for 30 min and migrated against AVP \[10-9 M\]. Migration towards medium served as the negative control, as positive control, migration against fMLP \[10-8 M\]. Statistical analyses: Mann-Whitney U test \[n.s., not significant, ^∗^, p\<0.05, ^∗∗^, p\<0.01, ^∗∗∗^, p\<0.0001\]](med-13-122-g003){#j_med-2018-0020_fig_003}

The strongest chemotactic responses to AVP were observed in the micro- and nanomolar range (10^--6^ to 10^--9^) for monocytes and in the nanomolar range (10^--9^) for neutrophils (p\<0.001). Migration significantly differed between pre-incubated and not pre-incubated neutrophils at low dilutions (10^--5^ p=0.023; 10^--7^ p=0.012) and monocytes at high dilution (10^--15^ p=0.007). With declining AVP concentration, the blocking effect of AVP on migration diminished. Checker-board analysis revealed that neutrophils ([Table 1 A](#j_med-2018-0020_tab_001){ref-type="table"}) only migrate in a chemotactic manner, but AVP revealed chemotactic and chemokinetic properties of monocytes ([Table 1B](#j_med-2018-0020_tab_001){ref-type="table"}).

###### 

Checkerboard analysis in response to AVP

  A\)                                                                                                       Vasopressin \[log M\]. upper chamber                                                                                                    
  ------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- -------------
  Vasopressin \[log M\] lower chamber                                                                                                                                                                                                               
  Medium                                1,000±0,000                                                         0,953±0,157                                                         1,098±0,051[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     1,154±0,134
  10-Jul                                1,105±0,058[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     0,935±0,128                                                         1,022±0,099                                                         1,088±0,081
  10-Sep                                0,982±0,117                                                         0,935±0,166                                                         1,073±0,112                                                         0,978±0,089
  10-Nov                                1,015±0,086                                                         1,012±0,144                                                         1,049±0,055                                                         1,046±0,095
  B\)                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                    
                                                                                                            **Vasopressin \[log M\]**.**upper chamber**                                                                                             
                                        **Medium**                                                          **10-Jul**                                                          **10-Sep**                                                          **10-Nov**
                                                                                                                                                                                                                                                    
  Vasopressin \[log M\] lower chamber                                                                                                                                                                                                               
  Medium                                1,000±0,000                                                         1,160±0,052[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   1,170±0,112[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   1,025±0,074
  10-Jul                                1,115±0,106[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   1,072±0,096[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     1,124±0,096[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   0,981±0,080
  10-Sep                                1,137±0,066[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   1,064±0,097                                                         1,094±0,093[^\*\*^](#j_med-2018-0020_fn_003){ref-type="table-fn"}   1,077±0,074
  10-Nov                                1,160±0,103[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     1,121±0,092[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     1,081±0,087[^\*^](#j_med-2018-0020_fn_001){ref-type="table-fn"}     1,024±0,117

PMNs (A) and monocytes (B) migrated in response to different concentrations of AVP. The upper wells were filled with cells supplemented with various concentrations of AVP. The lower wells were filled with medium (control), or different concentrations of AVP. Statistical analyses: Mann-Whitney U test \[n.s., not significant

p\<0.05

p\<0.01

3.2. Respiratory burst activity {#j_med-2018-0020_s_003_s_002}
-------------------------------

Following 10 min priming at 37°C with various concentrations of AVP, washing and re-suspension with HBSS and incubation with DCFH-DA, no release of oxygen free radicals was observed in neutrophils ([Fig. 4](#j_med-2018-0020_fig_004){ref-type="fig"}).

![In vitro effects of AVP on oxidative burst\
Oxidative burst of (A) unstimulated, (B) N-formyl-Met-Leu-Phe (fMLP) and (C) phorbol 12-myristate 13-acetate (PMA)-stimulated polymorphonuclear leukocytes (PMN); PMNs were incubated with various concentrations of AVP ranging from 10-7 to 10-11 M or control; Graph shows mean ± standard deviation; n = 5; RFU, relative fluorescence units.](med-13-122-g004){#j_med-2018-0020_fig_004}

4. Discussion {#j_med-2018-0020_s_004}
=============

In this preliminary investigation, we observed that pre-incubation of leukocytes with AVP decreased the migratory response of immune cells to other chemoattractants and homologous deactivation of the migratory response. Checkerboard analysis showed that AVP in varying concentrations had chemotactic influence on neutrophils and chemotactic and chemokinetic influence on monocytes.

From the results of our preliminary investigation we cannot tell whether the chemotactic effect of AVP is receptor-independent or not. We assume that the receptor will be similar to the AVP V1-receptor in human peripheral blood mononuclear cells \[[@j_med-2018-0020_ref_007]\]. To identify both, receptor and second messenger will be focus of our future research.

Shock related to various illnesses, including sepsis and hemorrhage, is a known complication and a cause of death of patients in intensive care. It is of paramount importance to extend our knowledge regarding immunomodulatory effects of vasopressors, in particular vasopressin, as used in the treatment of shock. Catecholamines, however, diminished the migratory response of immune cells as well \[[@j_med-2018-0020_ref_017]\], and procalcitonin, a marker and mediator of the immune system, was reported to reduce chemotaxis in human monocytes \[[@j_med-2018-0020_ref_011]\]. In our opinion, stress hormones and mediators of the acute-phase response, such as procalcitonin, are immunosuppressive since they decrease migration of leukocytes when administered in high doses for prolonged periods, and thus increase mortality.

In vasopressin-deficient rats with permanently decreased number of blood leukocytes and reduced macrophage activity, administration of vasopressin resulted in enhanced phagocytosis of peritoneal macrophages \[[@j_med-2018-0020_ref_018],[@j_med-2018-0020_ref_019]\]. On the one hand, increased vasopressin production may indicate developing chronic inflammatory disease \[[@j_med-2018-0020_ref_009], [@j_med-2018-0020_ref_020]\]. On the other hand, vasopressin may limit immune response as illustrated by vasopressin-induced reduction in TNF-mediated inflammation in the rat cremaster microcirculation \[[@j_med-2018-0020_ref_021]\]. In bacterial urinary tract infection, vasopressin even down-regulates chemokine secretion, thereby limiting host defense \[[@j_med-2018-0020_ref_022]\].

Doherty et al. reported that vasopressin does not stimulate migration of polymorphonuclear leukocytes \[[@j_med-2018-0020_ref_023]\]. The findings of our study show more precisely that there is an AVP dose-dependent induction of chemotaxis in the presence of another chemoattractant depending on its concentration. However, when neutrophils were pre-incubated with AVP, there was significant reduction of migration in the presence of another chemoattractant.

AVP failed to enhance superoxide anion release of macrophages in comparison to substance P \[[@j_med-2018-0020_ref_024]\]. This is consistent with our findings. Depending on the results of our preliminary investigation, further experimental and clinical research is planned to assess the influence of vasopressin on leukocyte function in patients with SIRS and septic shock. AVP stimulates dose-dependent migration of monocytes and neutrophils. However, preincubation of leukocytes with AVP decreased the migratory response to other chemoattractants. This is in line with the known effect of catecholamine on the migratory response of human leukocytes \[[@j_med-2018-0020_ref_018]\]. Procalcitonin, a marker and mediator of the immune system, has the same effect on human monocytes \[[@j_med-2018-0020_ref_012]\].

In our opinion, stress hormones and mediators of the acute-phase response, such as procalcitonin, are immunosuppressive since they decrease the migration of leukocytes if their serum levels rise substantially (the serum levels of procalcitonin rise 300- to-500-fold in shock or sepsis) or if they are given in non-physiological doses or over a long period of time such as administration of AVP during resuscitation and therapy of septic shock.

5. Limitations {#j_med-2018-0020_s_005}
==============

The disadvantage of our investigation method with blind well chemotaxis chamber was the time-consuming and labour-intensive nature of the isolation technique and processing and the microscopic evaluation. The determination and interpretation of results depended on the experience of the observer. The observer was not informed about the hypotheses of the study and followed clearly defined investigation standards. As all investigations were performed by only one person there was at least no interobserver variability in the readings.

6. Conclusion {#j_med-2018-0020_s_006}
=============

The preliminary results of our study show that pre-incubation of leukocytes with AVP decreased their migratory response to other chemoattractants. The strongest chemotactic responses to AVP were observed in the micro- and nanomolar range for monocytes and in the nanomolar range for neutrophils. AVP did not stimulate the release of oxygen free radicals in neutrophils.
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